JP2021533098A5 - - Google Patents

Info

Publication number
JP2021533098A5
JP2021533098A5 JP2021504376A JP2021504376A JP2021533098A5 JP 2021533098 A5 JP2021533098 A5 JP 2021533098A5 JP 2021504376 A JP2021504376 A JP 2021504376A JP 2021504376 A JP2021504376 A JP 2021504376A JP 2021533098 A5 JP2021533098 A5 JP 2021533098A5
Authority
JP
Japan
Prior art keywords
composition according
aav vector
seq
aav
administered
Prior art date
Application number
JP2021504376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533098A (ja
JPWO2020028830A5 (https=
JP7684212B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/044946 external-priority patent/WO2020028830A1/en
Publication of JP2021533098A publication Critical patent/JP2021533098A/ja
Publication of JP2021533098A5 publication Critical patent/JP2021533098A5/ja
Publication of JPWO2020028830A5 publication Critical patent/JPWO2020028830A5/ja
Application granted granted Critical
Publication of JP7684212B2 publication Critical patent/JP7684212B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021504376A 2018-08-03 2019-08-02 第viii因子の発現による改善された臨床パラメーター Active JP7684212B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862714553P 2018-08-03 2018-08-03
US62/714,553 2018-08-03
US201962826887P 2019-03-29 2019-03-29
US62/826,887 2019-03-29
US201962869445P 2019-07-01 2019-07-01
US62/869,445 2019-07-01
PCT/US2019/044946 WO2020028830A1 (en) 2018-08-03 2019-08-02 Improved clinical parameters by expression of factor viii

Publications (4)

Publication Number Publication Date
JP2021533098A JP2021533098A (ja) 2021-12-02
JP2021533098A5 true JP2021533098A5 (https=) 2022-08-09
JPWO2020028830A5 JPWO2020028830A5 (https=) 2022-08-09
JP7684212B2 JP7684212B2 (ja) 2025-05-27

Family

ID=69230742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504376A Active JP7684212B2 (ja) 2018-08-03 2019-08-02 第viii因子の発現による改善された臨床パラメーター

Country Status (10)

Country Link
US (1) US12497632B2 (https=)
EP (1) EP3829650A4 (https=)
JP (1) JP7684212B2 (https=)
KR (1) KR20210039428A (https=)
CN (1) CN112533645B (https=)
BR (1) BR112021001315A2 (https=)
CA (1) CA3105382A1 (https=)
IL (1) IL280402B1 (https=)
MX (1) MX2021001375A (https=)
WO (1) WO2020028830A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240066146A1 (en) 2020-12-18 2024-02-29 Sangamo Therapeutics, Inc. Improved pharmaceutical compositions containing adeno-associated viral vector

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5588298A (en) 1996-12-02 1998-06-29 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
CA2392863A1 (en) 2002-07-08 2004-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A high capacity recombinant adenoviral vector for treatment of hemophilia a
PL1675956T3 (pl) 2003-10-21 2011-06-30 Merck Serono Sa Minimalna sekwencja DNA działająca jako insulator chromatyny i jej zastosowanie do wyrażania białek
JPWO2006043354A1 (ja) 2004-10-20 2008-05-22 独立行政法人放射線医学総合研究所 組込型の低線量放射線誘導性ベクター
MX2007015540A (es) 2005-06-10 2008-03-07 Genentech Inc Mejora de la expresion de anticuerpos utilizando vectores que contienen elementos aislantes.
CN101965409A (zh) 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
EP4154903A1 (en) 2008-04-22 2023-03-29 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
WO2009134681A2 (en) * 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Aav7 viral vectors for targeted delivery of rpe cells
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
AU2012312260B2 (en) * 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
CN104114572A (zh) * 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
DK3444342T3 (da) 2012-07-11 2020-08-24 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
EP2911687B1 (en) 2012-10-26 2019-02-13 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
BR112015025041A2 (pt) 2013-03-30 2017-09-12 Usha Biotech Ltd métodos e conceitos para expressar proteínas biologicamente ativas em células de mamíferos
RS61039B1 (sr) 2013-09-12 2020-12-31 Biomarin Pharm Inc Aav vektori koji sadrže gen koji kodira faktor viii
DK3080274T3 (da) 2013-12-09 2020-08-31 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til genom-manipulation
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
KR102554850B1 (ko) 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
CN115074366A (zh) * 2015-04-16 2022-09-20 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
WO2016180755A1 (en) 2015-05-11 2016-11-17 Bayer Cropscience Aktiengesellschaft Herbicide combinations comprising l-glufosinate and indaziflam
EP3322297B1 (en) 2015-07-13 2024-12-04 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
RU2742352C2 (ru) 2015-09-24 2021-02-05 Байомарин Фармасьютикал Инк. Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
CA3002524A1 (en) 2015-10-28 2017-05-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor viii expression cassettes and methods of use thereof
EP3374387A1 (en) * 2015-11-13 2018-09-19 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
AU2018312565A1 (en) * 2017-08-01 2020-02-27 Spark Therapeutics, Inc. Factor VIII (FVIII) gene therapy methods

Similar Documents

Publication Publication Date Title
JP2022500066A5 (https=)
JP2024054426A5 (https=)
JP2022141670A5 (https=)
JP2023070682A5 (https=)
JP2020510428A5 (https=)
JP2020514286A5 (https=)
JP2020518268A5 (https=)
JP2021533805A5 (https=)
JPWO2020069461A5 (https=)
JP2021500922A5 (https=)
JP2020519292A5 (https=)
JP2024056832A5 (https=)
IL262852B1 (en) Treatment of complement-mediated disorders
JP2024119830A5 (https=)
JPWO2022032226A5 (https=)
JPWO2022053630A5 (https=)
JP2020527167A5 (https=)
JP2021533098A5 (https=)
JPWO2020142653A5 (https=)
IL321380A (en) Adeno-associated viral vectors for the treatment of best disease
JPWO2021181118A5 (https=)
JPWO2020028830A5 (https=)
JP2022514271A5 (https=)
JPWO2022178298A5 (https=)
RU2021104626A (ru) Улучшение клинических параметров посредством экспрессии фактора viii